Optimizing Single-Cell Cloning Workflows for iPSC Manufacturing

From Robust Clone Outgrowth to GMP-Ready Cell Banks

Ensuring the clinical reliability of iPSC-derived products begins with genetically stable and well-characterised starting materials.

This webinar presents a multilayer strategy designed to safeguard the genomic integrity of iPSCs and examines a Master Cell Bank manufacturing process based on single-cell cloning. By integrating the VIPS™ platform for image-verified single-cell cloning and seeding together with CellMetric for automated clonal outgrowth imaging, the workflow supports traceable, high-confidence clone selection, an essential foundation for GMP-ready Master Cell Banks and downstream clinical manufacturing.

This approach enables the identification and expansion of genetically intact clones, strengthening the overall safety profile, ensuring consistent batch manufacturing and supporting the clinical robustness of iPSC-based therapies.

The featured panellists will discuss a workflow-centric approach to optimising single-cell cloning for iPSC programs, spanning early clone establishment, culture condition selection and the transition toward GMP-ready Master and Working Cell Banks. Drawing on real-world development experience, the session will explore how media and matrix choices influence clonal performance, how cellular stress contributes to clonal drift and genetic instability and how upstream workflow design can mitigate these risks without relying on project-specific datasets.
The discussion will also highlight where single-cell recloning (“clonal reset”) and staged genetic integrity monitoring can be integrated into broader upstream strategies to support consistent, scalable and regulatory-ready iPSC manufacturing. Attendees will gain practical insight into building robust single-cell cloning workflows, supported by image-verified technologies, that balance scientific rigour with real-world development constraints.

Register for this webinar to learn how iPSC manufacturing workflows can support genetically stable clones, GMP-ready cell banks and consistent clinical manufacturing.

Who Should Attend
This webinar will appeal to:

• Cell Therapy Scientists and Developers working on iPSC derived clinical products
• Upstream Process Development and MSAT Scientists (CGT and iPSC)
• CDMO Platform teams supporting iPSC-based therapeutics
• Translational Research and Cell Banking teams preparing for GMP transfer
• Scientists responsible for single cell cloning, clone selection and early manufacturing decisions
• Anyone involved in designing robust, scalable and compliant iPSC workflows for therapeutic applications

What You Will Learn
Attendees will gain insight into:

• Why single-cell cloning variability is a major upstream risk factor in iPSC programs
• How media, matrix and handling conditions influence early clonal outgrowth and stability
• Where cellular stress contributes to clonal drift and genetic integrity risk
• When single-cell recloning can be used strategically to mitigate the effects of genomic instability
• Why genetically stable starting materials are essential for clinical grade iPSC manufacturing
• How to design upstream workflows that support GMP-ready iPSC banking that ensure high-quality starting materials

Register free on Xtalks:
https://xtalks.com/webinars/optimizing-single-cell-cloning-workflows-for-ipsc-manufacturing/